Monopar Therapeutics (NASDAQ:MNPR) Issues Earnings Results

Monopar Therapeutics (NASDAQ:MNPR) issued its quarterly earnings data on Wednesday. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.13), FiscalAI reports.

Monopar Therapeutics Trading Up 0.3%

MNPR traded up $0.34 on Wednesday, hitting $114.80. 238,702 shares of the company’s stock were exchanged, compared to its average volume of 221,662. The firm has a market cap of $769.05 million, a PE ratio of -60.42 and a beta of 1.47. Monopar Therapeutics has a twelve month low of $29.18 and a twelve month high of $124.82. The stock has a fifty day moving average of $92.93 and a two-hundred day moving average of $70.68.

Wall Street Analyst Weigh In

A number of brokerages recently commented on MNPR. HC Wainwright increased their price target on Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. Piper Sandler set a $105.00 target price on Monopar Therapeutics in a research report on Tuesday, June 2nd. Wall Street Zen raised shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday, July 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $112.08.

Hedge Funds Weigh In On Monopar Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC grew its stake in Monopar Therapeutics by 2.3% during the 4th quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company’s stock worth $85,908,000 after buying an additional 30,042 shares during the last quarter. RA Capital Management L.P. boosted its holdings in shares of Monopar Therapeutics by 30.5% during the fourth quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock valued at $43,569,000 after acquiring an additional 156,000 shares during the period. ADAR1 Capital Management LLC grew its position in shares of Monopar Therapeutics by 79.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 233,908 shares of the company’s stock worth $15,274,000 after acquiring an additional 103,909 shares during the last quarter. Wellington Management Group LLP bought a new position in shares of Monopar Therapeutics during the third quarter worth about $18,904,000. Finally, Siren L.L.C. acquired a new stake in shares of Monopar Therapeutics in the 4th quarter worth about $13,863,000. 1.83% of the stock is owned by institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.